Stem Cell Research, Lung Organoids & Cystic Fibrosis

Dr. Brigitte Gomperts, leads a lab at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Her research focuses on the role stem cells play in repairing and regenerating the lungs after injury; her lab was the first to use stem cells to create lung-like organoids that mimic the air sac structures of actual lungs that – among other things – are used for high-throughput drug screening, and which someday might lead to the generation of patient-specific transplantable lung tissue. CFRI endorses CA Proposition 14 to continue funding stem cell research. Dr. Gomperts’ work is an example of the vital research funded through the California Institute of Regenerative Medicine.

Recorded 10/26/2020

COVID-19 and Cystic Fibrosis: Q&A Session #12 with Rick Moss, MD - September 15, 2020.

Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past weeks related to testing, vaccine progress, returning to school and more. This most recent session was recorded on September 10, 2020.

We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, Chiesi USA, and Mylan Pharmaceuticals for their support of these podcasts.

Contraception in the Era of CFTR Modulators

On Tuesday July 21, 2020, CFRI hosted a webinar on Contraception in the Era of CFTR Modulators. Emily Godfrey, MD, MPH (University of Washington), Patricia Walker, MD (Mount Sinai Beth Israel, NY), Molly Pam and Laura Mentch (women with CF) discussed the epidemiology of unplanned pregnancy and contraceptive need among women with CF; how hormonal contraception may affect CF disease; and contraceptive considerations in the era of CFTR modulators.

CF Community Voices is sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA and Mylan Pharmaceuticals.

Bringing Patient Centered Outcomes Research to the CF Community

The vital impact of patient centered outcomes research is increasingly understood. Emily Godfrey, MD, MPH, Associate Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Washington, and Laura Mentch, adult with CF and patient-partner with the Cystic Fibrosis Reproductive and Sexual Health Collaborative (CFReSHC), share their expertise and experience in bringing patient centered outcomes research to the CF community.

We thank our sponsors, Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA and Mylan Pharmaceuticals.

Greet Me Germ Free - The Update

COVID-19 and Cystic Fibrosis: Q&A Session #11 with Rick Moss, MD - June 24, 2020

Rick Moss, MD, CF clinician and researcher at Stanford, answers CF and COVID-19-related questions submitted by our community over the past week related to antibody tests, impacts on those with CF, and much more. This session was recorded on June 24, 2020.

We thank Vertex Pharmaceuticals, Gilead Sciences, Genentech, and Chiesi USA for their support of these podcasts.

Track: Woods Artist: Federico Fabbiano Music provided by Oak Studios https://youtu.be/eAiAlg22gqQ

COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD

On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.

CF Community Voices is sponsored to date by Chiesi USA.

If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

COVID-19, Cystic Fibrosis & Vaccines: Q & A with Richard Moss, MD

On January 7, 2021, CFRI hosted a webinar with Dr. Rick Moss, CF clinician and researcher at Stanford. Dr. Moss gave an overview of the current state of the pandemic - including its impact upon those with cystic fibrosis - and answered questions from the CF community with a focus on vaccines.

CF Community Voices is sponsored to date by Chiesi USA.

If you watch this podcast episode, please let us know what you think at https://www.surveymonkey.com/r/TMRP766

A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH (Audio)

The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.

Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.

A Review of Lenabasum Phase II Clinical Trial Results - James Chmiel, MD, MPH

The role of anti-inflammatories in CF care is vital. Lenabasum, Corbus Pharmaceuticals' investigational drug that mimics the effects of endocannabinoids in regulating inflammation, has been tracked through the clinical trial process with tremendous optimism. Dr. Chmiel, Principal Investigator of CF-002 (lenabasum), and Division Chief for Pediatric Pulmonology, Allergy and Sleep Medicine at Indiana University School of Medicine, reviews the results of the recent Phase IIb trial, and its implications for the CF community.

Sponsored by Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, Genentech, and Viatris, with additional support from Corbus Pharmaceuticals.